• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Lexeo Therapeutics Inc.

    11/5/25 7:56:27 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email
    S-8 1 lxeo-20251105.htm S-8 S-8

    As filed with the Securities and Exchange Commission on November 5, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    LEXEO THERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

    Delaware

    85-4012572

    (State or other jurisdiction of incorporation or
    organization)

    (I.R.S. Employer Identification No.)

    345 Park Avenue South, Floor 6

    New York, New York, 10010

    (212) 547-9879

    (Address of principal executive offices, including zip code)

    Lexeo Therapeutics, Inc. 2025 Inducement Equity Incentive Plan

    (Full title of the plan)

    R. Nolan Townsend

    Chief Executive Officer

    Lexeo Therapeutics, Inc.

    345 Park Avenue South, Floor 6

    New York, New York 10010

    (212) 547-9879

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

     

    Megan J. Baier

    David G. Sharon

    Wilson Sonsini Goodrich & Rosati, P.C.

    1301 Avenue of the Americas

    New York, New York 10019

    (212) 999-5800

    Jenny R. Robertson

    Chief Legal Officer

    Lexeo Therapeutics, Inc.

    345 Park Avenue South, Floor 6

    New York, New York 10010

    (212) 547-9879

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ¨

    Accelerated filer

    ¨

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Lexeo Therapeutics, Inc. (the “Registrant”) for the purpose of registering 2,000,000 shares of common stock of the Registrant reserved for issuance under the Lexeo Therapeutics, Inc. 2025 Inducement Equity Incentive Plan.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 24, 2025;

    (2) The information incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, from its Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025;

    (3) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, as amended by the Registrant's Quarterly Report on Form 10-Q/A, filed with the SEC on May 15, 2025; the Registrant's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025; and the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025;

    (4) The Registrant’s Current Reports on Form 8-K, filed with the Commission on January 13, 2025, April 7, 2025, May 27, 2025, June 30, 2025, August 14, 2025, October 7, 2025 and October 17, 2025, in each case to the extent the information included in such reports is filed and not furnished;

    (5) All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than the reports, or portions thereof, deemed to have been furnished and not filed with the Commission) since the end of the fiscal year covered by the Annual Report referred to in (1) above; and

    (6) The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on November 1, 2023 (File No. 001-41855) under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    The Registrant is incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director and officer, except where the director authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law, or where the director or officer breached such person’s duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, or obtained an improper personal benefit, and except for any action by or in the right of the corporation against an officer. The Registrant’s amended and restated certificate of incorporation contains provisions that eliminate the liability of its directors and officers for monetary damages to the fullest extent permitted under applicable law.


    Section 145 of the Delaware General Corporation Law generally provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which such person is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe such conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    As permitted by the Delaware General Corporation Law, the Registrant’s amended and restated bylaws provide that: (i) the Registrant is required to indemnify its directors to the fullest extent not prohibited by the Delaware General Corporation Law; (ii) the Registrant may, in its discretion, indemnify its officers, employees and agents as set forth in the Delaware General Corporation Law; (iii) the Registrant is required, upon satisfaction of certain conditions, to advance all expenses incurred by its directors in connection with certain legal proceedings; (iv) the rights conferred in the bylaws are not exclusive; and (v) the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents.

    The Registrant has entered into indemnification agreements with its directors and executive officers that generally require it to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of the Registrant or any of its affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the Registrant’s best interests.

    The Registrant maintains a directors’ and officers’ liability insurance policy that covers its directors and officers with respect to certain liabilities, including liabilities arising under the Securities Act, or otherwise.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

    EXHIBIT INDEX

     

     

     

     

     

     

     

     

     

     

     

     

     

    Exhibit

    Number

    Incorporated by Reference

    Filed or
    Furnished
    Herewith

    Exhibit Description

    Form

    File No.

    Exhibit

    Filing Date

     

     

     

     

     

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation (as amended and currently in effect)

     

    8-K

     

    001-41855

     

    3.1

     

    November 7, 2023

     

     

    4.2

     

    Amended and Restated Bylaws (as amended and currently in effect)

     

    8-K

     

    001-41855

     

    3.2

     

    November 7, 2023

     

     

    4.3

     

    Amended and Restated Investors’ Rights Agreement, dated August 10, 2021, by and among the Registrant and certain of its stockholders

     

    S-1

     

    333-274777

     

    4.1

     

    September 29, 2023

     

     

    4.4

    Form of common stock certificate of the Registrant

    S-1/A

     

    333-274777

     

    4.2

     

    October 30, 2023

     

     

    4.5+

     

    2025 Inducement Equity Incentive Plan and related form agreements

     

    10-Q

     

    001-41855

     

    10.5

     

    November 5, 2025

     

     

    5.1

     

    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.

     

     

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of KPMG LLP, independent registered public accounting firm

     

     

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto)

     

     

     

     

     

     

     

     

     

    X


    24.1

     

    Power of Attorney (included on the signature page hereto)

     

     

     

     

     

     

     

     

     

    X

    107

     

    Filing fee table

     

     

     

     

     

     

     

     

     

    X

     

    + Indicates management contract or compensatory plan, contract or arrangement.

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York, on November 5, 2025.

     

    LEXEO THERAPEUTICS, INC.

    By:

    /s/ R. Nolan Townsend

    R. Nolan Townsend

    Chief Executive Officer

     

    Date: November 5, 2025

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of R. Nolan Townsend, Louis Tamayo and Jenny Robertson as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

    Signature

    Title

    Date

     

     

     

    /s/ R. Nolan Townsend

    R. Nolan Townsend

    Chief Executive Officer and Director

    (Principal Executive Officer)

    November 5, 2025

     

     

     

    /s/ Louis Tamayo

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

     

    November 5, 2025

     

    Louis Tamayo

     

     

     

     

    /s/ Mette Kirstine Agger

    Mette Kirstine Agger

    Director

    November 5, 2025

     

     

     

     

    /s/ Steven Altschuler

    Steven Altschuler, M.D.

    Director

    November 5, 2025

     

     

     

     

    /s/ Paula HJ Cholmondeley

    Paula HJ Cholmondeley

    Director

    November 5, 2025

     

     

     

     

    /s/ Brenda Cooperstone

    Brenda Cooperstone, M.D.

    Director

    November 5, 2025

     

     

     

     

    /s/ Reinaldo Diaz

    Reinaldo Diaz

    Director

    November 5, 2025

     

     

     

     

     

    /s/ Tolga Tanguler

    Tolga Tanguler

     

    Director

     

    November 5, 2025

     

     

     

     

     

    /s/ Tim Van Hauwermeiren

    Tim Van Hauwermeiren

     

    Director

     

    November 5, 2025

     

     


    Get the next $LXEO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    11/20/2025$19.00Overweight
    Cantor Fitzgerald
    10/15/2025$30.00Buy
    Guggenheim
    7/31/2025$20.00Outperform
    Oppenheimer
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    More analyst ratings

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

    FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participa

    11/5/25 7:36:55 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

    NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) ("Lexeo"), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection with the transaction and including the full exercise of the underwriters' option to purchase additional shares. In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per sh

    10/20/25 4:05:00 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

    NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement for gross proceeds to Lexeo of approximately $135 million, before deducting underwriting discounts and commissions and other expenses payable by Lexeo in connection with the transactions and excluding any exercise of the underwriters' option to purchase additional shares. All of the shares and pre-funded warrants are to be sold by Lexeo. Lexeo offered 15,625,000 shares of its common stock in the p

    10/16/25 11:29:54 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Lexeo Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $19.00

    11/20/25 8:07:20 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Lexeo Therapeutics with a new price target

    Guggenheim initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $30.00

    10/15/25 8:29:39 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Lexeo Therapeutics with a new price target

    Oppenheimer initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $20.00

    7/31/25 7:37:07 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    SEC Filings

    View All

    SEC Form EFFECT filed by Lexeo Therapeutics Inc.

    EFFECT - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    11/28/25 12:15:23 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Lexeo Therapeutics Inc.

    424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    11/26/25 4:29:12 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/20/25 4:30:17 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Townsend Richard Nolan sold $10,447 worth of shares (1,127 units at $9.27), decreasing direct ownership by 0.47% to 240,991 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:21:29 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Adler Eric sold $5,701 worth of shares (615 units at $9.27), decreasing direct ownership by 0.84% to 72,646 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:20:13 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Development Officer See Tai Sandi sold $3,578 worth of shares (386 units at $9.27), decreasing direct ownership by 0.59% to 65,476 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:19:10 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

    12/19/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

    Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

    11/13/24 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

    Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

    8/12/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Financials

    Live finance-specific insights

    View All

    Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

    Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

    10/30/24 6:14:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

    NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

    7/11/24 8:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 5:49:30 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 4:45:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 12:32:15 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care